|Mr. Timothy P. Walbert||Chairman, Pres & CEO||5.48M||N/A||1967|
|Mr. Paul W. Hoelscher||Exec. VP & CFO||1.88M||N/A||1965|
|Mr. Barry J. Moze||Exec. VP & Chief Admin. Officer||1.71M||1.35M||1954|
|Dr. Jeffrey W. Sherman M.D., F.A.C.P.||Exec. VP & Chief Medical Officer||1.55M||2.3M||1955|
|Mr. Andy Pasternak||Exec. VP & Chief Strategy Officer||1.79M||N/A||1971|
|Mr. Miles W. McHugh||Chief Accounting Officer & Sr. VP||N/A||N/A||1965|
|Ms. Tina E. Ventura||Sr. VP of Investor Relations||N/A||N/A||N/A|
|Mr. Brian K. Beeler||Exec. VP & Gen. Counsel||N/A||N/A||1973|
|Mr. Timothy Ayers||Chief Compliance Officer & VP||N/A||N/A||N/A|
|Mr. Geoffrey M. Curtis||Exec. VP of Corp. Affairs & Chief Communications Officer||N/A||N/A||1975|
Horizon Therapeutics Public Limited Company focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It operates in two segments, Orphan and Inflammation. Its medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare lysosomal storage disorder; ACTIMMUNE for chronic granulomatous disease and severe malignant osteopetrosis; RAYOS for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis (AS), polymyalgia rheumatica, primary systemic amyloidosis, asthma, chronic obstructive pulmonary disease, systemic lupus erythematosus, and other conditions; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and AS to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Horizon Therapeutics Public Limited Company’s ISS Governance QualityScore as of April 30, 2021 is 5. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 8; Compensation: 1.